Lucy Collins

Lucy Collins

Auto-generated profile, based on publicly available information

Lucy Collins

Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
LCLucy Collins
Lucy Collins
ARAlec Ronan
Alec Ronan
EHEvelyn Hutcheon
Evelyn Hutcheon
PEPeter R Ebeling
Peter R Ebeling
VGVivian Grill
Vivian Grill
HNHanh H Nguyen
Hanh H Nguyen
Osteoporosis is common, affecting more than 20% of women and 6% of men globally over the age of 50. Anti-resorptive drugs, bisphosphonates and denosumab, have been effective treatments for osteoporosis for more than 30 years. Rare complications of anti-resorptive therapy include medication-related osteonecrosis of the jaw and atypical femur fractures (AFF). The American Society for Bone and Mineral Research (ASBMR) proposed a case definition for these atypical femoral fractures in 2010, which was updated in 2013. However, atypical fractures at non-classical sites have been increasingly described. We aimed to systematically identify atypical fracture cases excluded from the ASBMR AFF case definition in patients receiving anti-resorptive medication for longer than 3 yr. A structured search of electronic databases, including PubMed, Medline (Ovid), Embase (Ovid), Cochrane, and Web of Sciences, and hand-searching of conference abstracts were undertaken. All full-text articles written in English describing an atypical fracture in patients (aged >18 yr) and receiving anti-resorptive medication for >3 yr were included, with data extracted and analyzed by two independent reviewers. Sixty-six articles were identified, describing 151 cases of atypical fractures in 114 individuals. The most frequent fracture site was the ulna, followed by the tibia. All patients were taking anti-resorptive treatment prior to or at the time of fracture, most frequently alendronate monotherapy (44%). Most commonly, fractures were transverse in nature (95%), following minimal or no trauma (96%), and non-comminuted (98%) with cortical thickening of the surrounding bone (69%). Anti-resorptive treatment was ceased following an atypical fracture in the majority (89%). Atypical fractures are rare and should not deter physicians from appropriate anti-resorptive therapy for osteoporosis. However, clinicians should be alert to their presence at additional sites to the femur. An update of the current ASBMR AFF case definition to include other skeletal sites could be timely.

8 August 2023 in JBMR Plus
Verified
Journal Article
Open access
LCLucy Collins
Lucy Collins
EBEmma Boehm
Emma Boehm
CLCatherine Luxford
Catherine Luxford
RCRoderick Clifton‐Bligh
Roderick Clifton‐Bligh
VGVivian Grill
Vivian Grill
Hypervitaminosis D as a cause of hypercalcemia may be due to vitamin D intoxication, granulomatous diseases, or abnormalities of vitamin D metabolism. The CYP24A1 gene encodes for the 24‐hydroxylase enzyme, which is responsible for the catabolism of 25‐hydroxyvitamin D (25(OH)D) and 1,25‐dihydroxyvitamin D (1,25(OH)2D). Mutations in CYP24A1 can result in elevated 1,25(OH)2D causing parathyroid hormone (PTH)‐independent hypercalcemia, hypercalciuria, nephrolithiasis, and nephrocalcinosis. We present the cases of two siblings exhibiting hypercalcemia secondary to a CYP24A1 loss‐of‐function mutation. Case 1 presented initially with PTH‐dependent hypercalcemia, with localization of a left upper parathyroid adenoma on parathyroid technetium sestamibi (99mTc‐MIBI) uptake study. Despite parathyroidectomy (180 mg adenoma), hypercalcemia, hypercalciuria, and low normal PTH levels persisted. A repeat parathyroid 99mTc‐MIBI uptake study localized a second adenoma and a right inferior parathyroidectomy was performed (170 mg adenoma). PTH subsequently became undetectable, however hypercalcemia and hypercalciuria persisted. A new presentation of PTH‐independent hypercalcemia found to be secondary to a CYP24A1 loss‐of‐function mutation in his sibling, Case 2, signaled the underlying cause. Cascade testing confirmed both siblings were homozygous for the pathogenic variant c.1186C>T, p.Arg396Trp (R396W) of CYP24A1 (NM_000782.5). In clinical practice CYP24A1 loss‐of‐function mutations should be considered in patients presenting with PTH‐independent hypercalcemia, hypercalciuria, and 1,25(OH)2D levels in the upper normal or elevated range. Although in our case assays of 24,25(OH)2D were not available, calculation of the 25(OH)D:24,25(OH)2D ratio can assist in the diagnostic process. Possible treatments to manage the risk of hypercalcemia in patients with a CYP24A1 loss‐of‐function mutation include avoidance of vitamin D oversupplementation and excessive sun exposure. Hydration and bisphosphonate therapy can be useful in managing the hypercalcemia. Although not utilized in our cases, treatment with ketoconazole, fluconazole, and rifampicin have been described as potential therapeutic options. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

25 February 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
AFAhmed M Fathalla
Ahmed M Fathalla
CCCherie Chiang
Cherie Chiang
RARalph Audehm
Ralph Audehm
AGAlexandra Gorelik
Alexandra Gorelik
SCShanton Chang
Shanton Chang
JWJohn D Wark
John D Wark
Background: The lack of osteoporosis treatment initiation after fragility fractures is a significant gap, especially in primary care. It is unclear whether barriers for primary care physicians (PCPs) arise from uncertainty about investigations, treatment initiation, or medication side effects. Key questions remain about whether active learning platforms improve treatment initiation rates better than passive methods and how PCP demographics affect learning outcomes. With PCPs increasingly using web-based platforms for continuing professional development due to time constraints and heavy workloads, an interactive community fracture capture (CFC) tool may serve as an effective alternative to in-person learning. Our CFC pilot study tested this new program’s design and content, showing promising potential. Objective: We aim to evaluate the interactive, case-based, web-based CFC Learning Hub, examining user acceptance and engagement with the platform, focusing on participants’ interactions, satisfaction levels, and overall experience. Methods: Participating PCPs are recruited through Praxhub, a web-based medical education platform, and provide electronic consent for data use after deidentification. They have been allocated into small groups (12-20 members) and join the CFC Learning Hub, a secure web-based community. This hub includes a web-based discussion forum with participant-contributed case studies and a knowledge repository. Over the 6-week program, participants will receive weekly modules with instructions, resources, discussion threads, and quizzes, along with interactive discussions moderated by experienced PCPs and physicians. The platform also hosts web-based surveys that, in combination with platform analytics, allow assessment of baseline knowledge gaps, level of activity or engagement, and improvements following the course completion. This study protocol demonstrates the creation and proposed evaluation of the CFC Learning Hub, featuring an interactive, case-based, small-group web-based learning platform equipped with flexibly scheduled, tailored modules to address the fracture treatment gap within the community. Both qualitative (via thematic analysis) and quantitative (by using 2-tailed paired t tests, Wilcoxon signed rank tests, and multivariable regression analysis) analyses will be used to assess levels of engagement and acceptance and changes in PCPs’ knowledge and confidence after engagement with the CFC Learning Hub. Results: Recruitment of participants started in May 2022. Data collection, analysis, and reporting will be completed following the completion of four 6-week cycles of the program. Conclusions: The study described in this protocol will provide important insights into the function and effectiveness of the CFC Learning Hub. This information will guide the expansion of the program. This initiative offers a simple digital solution for promoting current bone health practices tailored to PCPs’ needs and thereafter to expand the rollout of the e-learning hub and implementation of fracture liaison models at a primary care level in Australia and elsewhere. Future applications may extend to other clinical areas and professions. International Registered Report Identifier (IRRID): DERR1-10.2196/57511

7 October 2025 in Current Osteoporosis Reports
Verified
Journal Article
Open access
PDF file
LCLucy Collins
Lucy Collins
HNHanh H. Nguyen
Hanh H. Nguyen
FMFrances Milat
Frances Milat
Peter  EbelingPeter Ebeling
Peter Ebeling
Purpose of review: To summarise recent publications addressing the epidemiology, pathogenesis and management of atypical femur fractures (AFFs). Recent findings: AFFs have been reported in anti-resorptive treated individuals, bisphosphonate-naïve individuals and individuals with monogenic bone diseases. The likelihood of developing an AFF increases with prolonged exposure to anti-resorptive treatment. AFF risk declines following anti-resorptive discontinuation. Asian ethnicity has emerged as an important risk factor for AFF. Although excluded from the current ASBMR AFF case definition, periprosthetic AFFs and atypical fractures at non-classical sites have been increasingly reported. Following an AFF, anti-resorptive therapy should be discontinued, surgical treatment with intramedullary nailing considered, the contralateral femur imaged, and the underlying osteoporosis addressed. Emerging evidence suggests teriparatide may aid healing in surgically managed AFFs but not in conservatively managed incomplete AFFs. Summary: AFFs remain a rare side effect of anti-resorptive treatment. Emerging areas of interest and further research include genetic and ethnic risk factors and advancements in diagnostic technologies for AFFs.

6 December 2025 in JBMR Plus
Verified
Journal Article
Open access
LCLucy Collins
Lucy Collins
JSJessica Sandy
Jessica Sandy
SLStephanie Ly
Stephanie Ly
KLKate E Lomax
Kate E Lomax
SBSarah Black
Sarah Black
ASAris Siafarikas
Aris Siafarikas
Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) and generalized arterial calcification of infancy (GACI) occur secondary to biallelic ectonucleotide pyrophosphate/phosphodiesterase 1 (ENPP1) loss-of-function pathogenic variants. GACI is a life-threatening condition, often presenting in the neonatal period with heart failure and hypertension, caused by calcification of the media in large- and medium-sized arteries. ARHR2 typically manifests later in life. Children with ARHR2 commonly exhibit short stature, rachitic skeletal changes, progressive deformities of the lower limbs, skeletal fragility and bone/muscle pain. We present six cases of homozygous pathogenic variants in the ENPP1 gene causing ARHR2 and/or GACI. Case 1: Presented with lower limb deformities and pain with radiological evidence of rickets. Subsequent investigations displayed aortic and pulmonary arterial calcification. Case 2: Presented with lower limb deformities and knee pain. Confirmatory testing was undertaken following her brother’s (Case 1) diagnosis. Case 3: The diagnosis was made antenatally. Bisphosphonate treatment was instituted in both the pre- and post-natal periods due to the presence of extensive arterial calcifications. Rickets were noted by two years of age. Case 4: Presented with lower limb deformities and pain. There is neither any current evidence of arterial calcification nor hypertension. Case 5: Presented at 3 mo of age in cardiogenic shock with widespread calcification of large and medium-sized arteries. Bisphosphonate treatment was instituted. Case 6: Presented at 2 wk of age with right shoulder discomfort, with evidence of glenohumeral joint calcification. Further imaging revealed aortic, mediastinal, sternoclavicular joint and vertebral spinous process calcification. Case 1 and 2 were also found to have a heterozygous pathogenic ALPL variant consistent with hypophosphatasia. Clinical features, biochemistry, imaging and genetic analyses assist in the diagnosis of ARHR2 and GACI. Conventional therapy, oral phosphate and calcitriol for ARHR2 and bisphosphonates for GACI, have been utilized for many years. ENPP1 replacement treatment remains an exciting prospect for future management of ARHR2 and GACI secondary to loss of function of ENPP1.

21 January 2026 in JMIR Formative Research
Verified
Journal Article
Open access
AFAhmed M Fathalla
Ahmed M Fathalla
CCCherie Chiang
Cherie Chiang
RARalph Audehm
Ralph Audehm
AGAlexandra Gorelik
Alexandra Gorelik
SCShanton Chang
Shanton Chang
JWJohn D Wark
John D Wark
Background: The lack of osteoporosis treatment initiation following fragility fractures is a recognized gap, particularly in primary care. Primary care physicians’ (PCPs) barriers to treatment, such as uncertainties in investigation, initiation, and concerns about drug side effects, remain challenging. It is also unclear whether knowledge gaps and barriers vary by region or if active learning platforms are more effective than passive methods in improving treatment rates, and how PCP demographics influence learning outcomes. With time constraints, PCPs are increasingly using online platforms for continuing professional development, and the interactive online Community Fracture Capture (CFC) tool has emerged as a promising alternative to traditional methods. Our CFC pilot study tested this program’s design and content, revealing its potential effectiveness. Objective: The study aimed to assess the operational characteristics, educational effectiveness, and acceptability of the interactive online CFC model in enhancing Australian PCPs’ knowledge and skills in community-based fracture treatment. Additionally, it sought to examine how PCPs’ knowledge and treatment gaps relate to their demographic characteristics and clinical practice backgrounds. Methods: The CFC Learning Hub is a secure, adaptable online platform that promotes community learning. It includes an interactive forum where participants share case studies and engage in discussions with bone specialists and senior PCP facilitators. The hub also offers a knowledge repository and allows participants to post inquiries. Online surveys and back-end analytics track baseline knowledge, activity levels, and improvements in knowledge and confidence over time, offering insights into participants’ learning and program development. Results: Four 6-week small-group cycles involved 55 PCPs, with over 80% working in metropolitan-based practices and a median (IQR) of 22 (16-34) years in practice. Topic modules covered osteoporosis diagnostics, treatment, monitoring, and challenging conditions, using a multidisciplinary approach with participant case studies. A total of 35 (64%) PCPs provided evaluation data, with 86% (n=30) joining to learn from experts or improve patient management and 83% (n=29) being satisfied with the content. Preferred learning methods included small group learning (n=13, 37%), live webinars (n=9, 26%), interactive learning (n=7, 20%), and on-demand videos (n=6, 17%), and 57% (n=20) found the platform easy to use. The most popular access times were evening (n= 23, 66%) and weekends (n=10, 29%). At completion, 89% (n=31) would recommend the training, and 78% (n=22 out of 28 respondents to the postprogram expectations meeting survey) were fully satisfied that their training needs were met, with 22% (n=6) partly satisfied. In addition, following the course completion, almost everyone reported being confident or very confident in managing osteoporosis. Conclusions: The CFC program was created by bone specialists, PCPs, software engineers, and information technology specialists. This collaboration produced a user-friendly, case-based, interactive, time-flexible, and highly acceptable program bridging investigation and management gaps in osteoporosis. It is customized to address challenges faced by PCPs and is potentially relevant for implementation in a wide range of fields, both health-related and others.